Medannex Ltd (Edinburgh) today revealed details of the ATTAINMENT study at the American Society of Clinical Oncology (ASCO) Annual Meeting.
The Phase 1b oncology study is the first clinical evaluation of a therapy targeting annexin-A1, a new and unique cancer target.
Full details here: https://medannex.org/medannex-unveils-first-in-human-study-of-novel-cancer-therapy-at-asco-2024/